Retatrutide Research Hub — Triple Incretin Agonist Studies
Retatrutide is an investigational triple agonist at the GLP-1, GIP, and glucagon receptors widely cited in metabolic-research models. This hub compiles the comparative literature across the incretin-agonist family.
What this hub covers
- GLP-1 / GIP / glucagon triple receptor agonism
- Energy-expenditure and body-composition literature
- Comparisons to tirzepatide (dual) and semaglutide (mono)
- Comparisons to survodutide (dual GLP-1 / GCG)
- Reconstitution and storage
Retatrutide research articles
All research →Retatrutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and tirzepatide/semaglutide comparisons for Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist with the largest body-weight reductions reported for any non-surgical incretin pharmacotherapy.
Read article →Retatrutide vs Semaglutide — Research Comparison
Side-by-side research comparison of retatrutide (GLP-1/GIP/glucagon triple agonist) and semaglutide (GLP-1 mono-agonist) — mechanism, pharmacokinetics, and metabolic-research literature.
Read article →Retatrutide vs Tirzepatide — Research Comparison
Triple agonist (retatrutide) vs dual agonist (tirzepatide) — side-by-side research comparison of receptor targets, pharmacokinetics, and published metabolic data.
Read article →Retatrutide Dosing & Protocols — Research Reference
Reference compilation of retatrutide titration, dosing tiers, and triple-agonist endpoint markers from published research.
Read article →Cagrilintide vs Semaglutide: Amylin and GLP-1 Pathways
A laboratory comparison of amylin-receptor and GLP-1-receptor signaling, with controls for combined CagriSema research designs.
Read article →Tirzepatide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and semaglutide/Retatrutide comparisons for tirzepatide — the GLP-1/GIP dual agonist that established GIP-receptor co-agonism as a productive metabolic axis.
Read article →Semaglutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and cardiovascular-outcomes evidence for semaglutide — the most extensively characterised GLP-1 receptor agonist in the modern incretin literature.
Read article →Survodutide Benefits and Side Effects: A Research Guide
Research guide on Survodutide (BI 456906): dual GLP-1 / glucagon receptor agonism, MASLD and metabolic literature, and the documented side-effect profile.
Read article →Retatrutide Reconstitution & Storage — Research Guide
Reference guide for retatrutide reconstitution ratios, BAC water volumes, triple-agonist concentration tables, refrigerated stability, and titration practice.
Read article →Semaglutide Reconstitution & Storage — Research Guide
Reference guide for semaglutide reconstitution ratios, bacteriostatic water volumes, concentration tables, refrigerated stability, and titration handling practice.
Read article →Tirzepatide Reconstitution & Storage — Research Guide
Reference guide for tirzepatide reconstitution, BAC water volumes, dual-agonist concentration tables, refrigerated stability, and titration handling practice.
Read article →Retatrutide Side Effects — Laboratory Research Reference
Reported tolerability of the triple GIP/GLP-1/glucagon agonist retatrutide across published Phase 2 data: dose-related GI adverse events, heart-rate effects, and titration considerations referenced for research context.
Read article →Retatrutide research FAQ
- What is Retatrutide?
- Retatrutide is an investigational triple agonist at the GLP-1, GIP, and glucagon receptors, widely cited in metabolic and energy-balance research.
- How does Retatrutide differ from tirzepatide and semaglutide?
- Semaglutide is a GLP-1 mono-agonist; tirzepatide is a GLP-1 / GIP dual agonist; Retatrutide adds glucagon-receptor agonism on top — adding an energy-expenditure axis described in the published literature.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.